Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes

被引：7
作者：
Yao, Fan [1 ]
Chen, Li [1 ,2 ]
Fan, Zheng [1 ]
Teng, Fei [1 ]
Zhao, Yali [1 ]
Guan, Fengying [1 ]
Zhang, Ming [1 ]
Liu, Yanjun [3 ]
机构：
[1] Jilin Univ, Dept Pharmacol, Coll Basic Med Sci, Changchun 130021, Peoples R China
[2] Jilin Univ, Sch Nursing, Changchun 130021, Peoples R China
[3] Univ Calif Los Angeles, Sch Med, Div Endocrinol Metab & Mol Med, Charles R Drew Univ Med & Sci, Los Angeles, CA USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2017年 / 27卷 / 17期
基金：
中国国家自然科学基金;
关键词：
H6PDH; 11; beta-HSD1; Corticosterone; Liver; Type 2 diabetes mellitus; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEXOSE-6-PHOSPHATE DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; INSULIN-RESISTANCE; DB/DB MICE; EXPRESSION; CONTRIBUTE; OBESITY; HYPERGLYCEMIA; HEPATOCYTES;
D O I：
10.1016/j.bmcl.2017.07.043
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Extensive studies have been performed on the role of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) in metabolic diseases. Our previous study reported glucose could directly regulate hexose-6-phosphate dehydrogenase (H6PDH) and 11 beta-HSD1. Recently, we further investigated the interplay of H6PDH and 11 beta-HSD1 and their roles in hepatic gluconeogenesis and insulin resistance to elucidate the importance of H6PDH and 11 beta-HSD1 in pathogenesis of type 2 diabetes mellitus (T2DM). T2DM rats model and H6PDH or 11 beta-HSD1 siRNA transfected in CBRH-7919 cells were used to explore the effect of H6PDH and 11 beta-HSD1 in T2DM. The results showed that the expression and activity of H6PDH and 11 beta-HSDI in livers of diabetic rats were increased, with the expressions of PEPCK and G6Pase or liver corticosterone increased apparently. It also showed that H6PDH siRNA and 11 beta-HSD1 siRNA could inhibit the protein expression and enzyme activity by each other. With H6PDH siRNA, the enhancement of gluconeogenesis was blocked and insulin resistance stimulated by corticosterone was reduced. H6PDH and 11 beta-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4107 / 4113
页数：7
相关论文
共 34 条
  • [31] Altered amino acid metabolism between coronary heart disease patients with and without type 2 diabetes by quantitative 1H NMR based metabolomics
    Zhang, Lili
    Zhang, Yifan
    Ma, Zhihui
    Zhu, Yanrong
    Chen, Zhong
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 206
  • [32] Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes
    Xiong, Yusheng
    Guo, Jian
    Candelore, Mari R.
    Liang, Rui
    Miller, Corey
    Dallas-Yang, Qing
    Jiang, Guoqiang
    McCann, Peggy E.
    Qureshi, Sajjad A.
    Tong, Xinchun
    Xu, Shiyao Sherrie
    Shang, Jackie
    Vincent, Stella H.
    Tota, Laurie M.
    Wright, Michael J.
    Yang, Xiaodong
    Zhang, Bei B.
    Tata, James R.
    Parmee, Emma R.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (13) : 6137 - 6148
  • [33] Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy
    Horie, Ichiro
    Haraguchi, Ai
    Sako, Ayaka
    Akeshima, Junya
    Niri, Tetsuro
    Shigeno, Riyoko
    Ito, Ayako
    Nozaki, Aya
    Natsuda, Shoko
    Akazawa, Satoru
    Mori, Yoshitaka
    Ando, Takao
    Kawakami, Atsushi
    Abiru, Norio
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 144 : 161 - 170
  • [34] Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume
    Acton, John J., III
    Akiyama, Taro E.
    Chang, Ching H.
    Colwell, Lawrence
    Debenham, Sheryl
    Doebber, Thomas
    Einstein, Monica
    Liu, Kun
    McCann, Margaret E.
    Moller, David E.
    Muise, Eric S.
    Tan, Yugen
    Thompson, John R.
    Wong, Kenny K.
    Wu, Margaret
    Xu, Libo
    Meinke, Peter T.
    Berger, Joel P.
    Wood, Harold B.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (13) : 3846 - 3854
1234